Results 21 to 30 of about 12,682 (143)
Opposite metabolic response to fenofibrate treatment in pregnant and virgin rats
Journal of Lipid Research, 2002 The level of maternal circulating triglycerides during late pregnancy has been correlated to newborns' weight in humans. To investigate the response to fenofibrate, a hypotriglyceridemic agent, in pregnant rats, 0, 100, or 200 mg of fenofibrate/kg body ...
Ana Soria, Carlos Bocos, Emilio Herrera
doaj +1 more source
BMC Ophthalmology, 2018 Background Previous studies suggested that use of fenofibrate could significantly reduce the rate of progression into diabetic retinopathy (DR), and that retinal nerve fiber layer (RNFL) loss, which has been considered an important indicator for retinal ...
Rui Shi, Lei Zhao, Yun Qi
doaj +1 more source
Italian Journal of Animal Science, 2022 So far, the effect of fenofibrate on the performance, quantitative and qualitative characteristics of broilers have not been investigated. For this reason, this study was performed to evaluate the effects of different levels of fenofibrate on the ...
Maryam Azizi +2 more
doaj +1 more source
EBioMedicine, 2016 Neovascular eye diseases including retinopathy of prematurity, diabetic retinopathy and age-related-macular-degeneration are major causes of blindness.
Yan Gong +14 more
doaj +1 more source
Small heterodimer partner-targeting therapy inhibits systemic inflammatory responses through mitochondrial uncoupling protein 2. [PDF]
PLoS ONE, 2013 The orphan nuclear receptor, small heterodimer partner (SHP), appears to play a negative regulatory role in innate immune signaling. Emerging evidence warrants further study on the therapeutic targeting of SHP to suppress excessive and deleterious ...
Chul-Su Yang +8 more
doaj +1 more source
Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review [PDF]
Diabetes & Metabolism JournalHypertriglyceridemia and decreased high-density lipoprotein cholesterol (HDL-C) persist despite statin therapy, contributing to residual atherosclerotic cardiovascular disease (ASCVD) risk.
Chaicharn Deerochanawong +2 more
doaj +1 more source
Additive Renoprotection by Pioglitazone and Fenofibrate against Inflammatory, Oxidative and Apoptotic Manifestations of Cisplatin Nephrotoxicity: Modulation by PPARs. [PDF]
PLoS ONE, 2015 Nephrotoxicity is a major side effect for the antineoplastic drug cisplatin. Here, we employed pharmacological, biochemical, and molecular studies to investigate the role of peroxisome proliferator-activated receptors (PPARs) in cisplatin nephrotoxicity.
Mai M Helmy +2 more
doaj +1 more source
Biomedical Sciences and Clinical Medicine, 2022 Fenofibrate, a lipid lowering drug, can increase the effects of warfarin and may cause bleeding more easily. We report a case of a 58-year-old Thai male patient who was administered warfarin at 27 mg per week to achieve the target international ...
Kanokwan Thitiratamornkit +2 more
doaj +1 more source
Mesoporous Silica Nanoparticles in Biomedicine: Advances and Prospects
Advanced Materials, EarlyView.Mesoporous silica nanoparticles offer unique properties like high surface area, tunable pores, and functionalization. They excel in drug delivery, tissue engineering, and stimuli‐responsive therapies, enabling targeted and controlled treatments. With roles in cancer therapy and diagnostics, their clinical translation requires addressing challenges in ...
Miguel Manzano, María Vallet‐Regí
wiley +1 more source
Scientific ReportsDiabetic corneal neuropathy (DCN) is a common diabetic ocular complication with limited treatment options. In this study, we investigated the effects of topical and oral fenofibrate, a peroxisome proliferator-activated receptor-α agonist, on the ...
Hassan Mansoor +10 more
doaj +1 more source